Specialty Pharmaceuticals Businesses for Sale and Investment Opportunities in Hyderabad

Specialty pharma marketing company with a focus on gynaecology and orthopaedics products. - Located in Hyderabad, Telangana, the company achieves monthly sales of approximately INR 12 to 15 lakh. - The product portfolio primarily consists of gynecologic and orthopaedic products, with gynecologic items being the top-selling category. - Serving a diverse clientele including multi-specialty hospitals, clinics, and pharmacies, ensuring wide market access. - The business is fully registered with GST and has a valid Certificate of Incorporation, enhancing credibility. - The sale includes all registered product brands and existing inventory, offering immediate operational capability for the buyer. - Currently not USFDA approved and all brands are registered but not trademarked, presenting opportunities for future brand development and market expansion. - A dedicated team of 13 employees is in place to facilitate a smooth transition for new ownership.

We are working with five clients. We are a research-based product development partner to pharmaceutical companies. Promoter experience: Promoter is a pharmaceutical professional with 18+ years of work experience (Formulation scientist) turned to healthcare entrepreneur. In 3 years, business will reach USD 2 million revenue per year. We signed up new clients this year and have already achieved INR 1 Cr for this year. More clients are in the pipeline. We generate almost equal revenue from fee for service model and in-house asset sale model.

We are working with five clients. We are a research-based product development partner to pharmaceutical companies. Promoter experience: Promoter is a pharmaceutical professional with 18+ years of work experience (Formulation scientist) turned to healthcare entrepreneur. In 3 years, business will reach USD 2 million revenue per year. We signed up new clients this year and have already achieved INR 1 Cr for this year. More clients are in the pipeline. We generate almost equal revenue from fee for service model and in-house asset sale model.